Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6594480 | 0.80 | ALDH1A1 (0.34) | LMNANPSR1HTT | |
| SCHEMBL3557090 | 0.79 | SMN1; SMN2 (0.37) | LMNAHTT | |
| SCHEMBL1447502 | 0.77 | HTT (0.40) | LMNARIPK1CHRNA4HTT | |
| SCHEMBL4021989 | 0.75 | TRPM8 (0.36) | LMNACHRNA4TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4027824 | 0.68 | LMNA (0.45) | LMNARIPK1CHRNA4NPSR1TAS1R3 | |
| SCHEMBL6593091 | 0.67 | MLYCD (0.33) | LMNANPSR1HTT | |
| SCHEMBL4025575 | 0.67 | LMNA (0.51) | LMNACHRNA4NPSR1TAS1R3TAS1R1 | |
| SCHEMBL1447382 | 0.66 | LMNA (0.54) | LMNACHRNA4NPSR1TAS1R3TAS1R1 | |
| SCHEMBL4027100 | 0.65 | LMNA (0.37) | LMNARIPK1CHRNA4TAS1R3TAS1R1 | |
| SCHEMBL4251064 | 0.65 | LMNA (0.52) | LMNANPSR1TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1828183-A1 | 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006064251-A1 | 4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | LMNA 1009/4885RIPK1 2708/4885CHRNA4 4594/4885 |
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | LMNA 883/4885RIPK1 4035/4885CHRNA4 4770/4885 |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | LMNA 1429/4885RIPK1 3880/4885CHRNA4 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.